{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:00:44Z","timestamp":1781020844427,"version":"3.54.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP23K06236"],"award-info":[{"award-number":["JP23K06236"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Foundation for Pharmaceutical Sciences"},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019890","name":"University of Miyazaki Hospital","doi-asserted-by":"crossref","award":["Clinical Research Support Grant"],"award-info":[{"award-number":["Clinical Research Support Grant"]}],"id":[{"id":"10.13039\/100019890","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tacrolimus is an essential immunosuppressant drug used during transplantation; however, its blood concentration must be carefully managed. Recent evidence suggests that tacrolimus concentrations in peripheral blood mononuclear cells (PBMCs) better reflect immunosuppressive activity than whole blood concentrations. In this study, the authors investigated the effect of extracellular FK506-binding protein (FKBP)12, a high-affinity tacrolimus-binding protein, on tacrolimus-mediated T-cell suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Human whole blood and purified PBMCs were stimulated with phytohemagglutinin-L to induce cytokine (interleukin-2, interferon-gamma) production. Tacrolimus accumulation in PBMCs was quantified using supercritical fluid chromatography\u2013tandem mass spectrometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Tacrolimus inhibited cytokine release in a concentration-dependent manner; however, extracellular FKBP12 significantly attenuated this effect. Extracellular FKBP12 reduced intracellular tacrolimus concentrations in a concentration-dependent manner, suggesting that extracellular FKBP12 binds tacrolimus, limiting its transfer into T cells and diminishing its immunosuppressive effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The results underscore the potential impact of extracellular FKBP12 on tacrolimus pharmacodynamics and highlight the importance of monitoring PBMC tacrolimus concentrations and considering extracellular FKBP12 as a factor influencing drug distribution and efficacy. The study findings provide a novel perspective for refining therapeutic drug monitoring and advancing personalized immunosuppressive therapy in transplantation medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001487","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:25:38Z","timestamp":1781018738000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Extracellular FKBP12 Inhibits Tacrolimus Translocation to Peripheral Blood Mononuclear Cells Reducing Immunosuppressive Effects: An In Vitro Study"],"prefix":"10.1097","author":[{"given":"Naoki","family":"Yoshikawa","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Oita, Japan;"},{"name":"Department of Pharmacy, University of Miyazaki Hospital, Miyazaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Yamada","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Takeda","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusei","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Miyazaki Hospital, Miyazaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Shibata","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Moritake","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Miyazaki Hospital, Miyazaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"R1-20260609","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): molecular and cellular mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R2-20260609","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00003495-200059020-00021","article-title":"Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation","volume":"59","author":"Plosker","year":"2000","journal-title":"Drugs"},{"key":"R3-20260609","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/bbmt.1999.v5.pm10371361","article-title":"Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation","volume":"5","author":"Przepiorka","year":"1999","journal-title":"Biol Blood Marrow Transpl"},{"key":"R4-20260609","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/17425255.2019.1675635","article-title":"Tacrolimus in adult hematopoietic stem cell transplantation","volume":"15","author":"Gao","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R5-20260609","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/cpt.1618","article-title":"Intrapatient variability of tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome","volume":"107","author":"Kuypers","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20260609","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/ph14040353","article-title":"Relationship between CYP3A5 polymorphism and tacrolimus blood concentration changes in allogeneic hematopoietic stem cell transplant recipients during continuous infusion","volume":"14","author":"Yoshikawa","year":"2021","journal-title":"Pharmaceuticals"},{"key":"R7-20260609","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0090-9556(25)07474-4","article-title":"Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance","volume":"21","author":"Piekoszewski","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"R8-20260609","first-page":"610","article-title":"Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion","volume":"25","author":"Chow","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"R9-20260609","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1600-6143.2011.03486.x","article-title":"Reduced-dose tacrolimus with mycophenolate mofetil vs. Standard-dose tacrolimus in liver transplantation: a randomized study","volume":"11","author":"Boudjema","year":"2011","journal-title":"Am J Transpl"},{"key":"R10-20260609","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1517\/14656566.2015.1056734","article-title":"Advances in pharmacotherapy to treat kidney transplant rejection","volume":"16","author":"Bamoulid","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R11-20260609","doi-asserted-by":"crossref","first-page":"e4416","DOI":"10.1002\/bmc.4416","article-title":"Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography\u2013tandem mass spectrometry","volume":"33","author":"Bahmany","year":"2019","journal-title":"Biomed Chromatogr"},{"key":"R12-20260609","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/pgs.10.43","article-title":"CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation","volume":"11","author":"Capron","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R13-20260609","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1432-2277.2011.01365.x","article-title":"Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study","volume":"25","author":"Capron","year":"2012","journal-title":"Transpl Int"},{"key":"R14-20260609","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11095-020-02875-z","article-title":"Role of FK506 binding protein on tacrolimus distribution in red blood cells","volume":"37","author":"Yoshikawa","year":"2020","journal-title":"Pharm Res"},{"key":"R15-20260609","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R16-20260609","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/phar.2653","article-title":"Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients","volume":"42","author":"Adie","year":"2022","journal-title":"Pharmacotherapy"},{"key":"R17-20260609","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/17425255.2023.2250251","article-title":"Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs","volume":"19","author":"Schagen","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R18-20260609","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0000000000001119","article-title":"Effect of tacrolimus time in therapeutic range on postoperative recurrence in patients undergoing liver transplantation for liver cancer","volume":"46","author":"Lao","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R19-20260609","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1038\/s41598-025-87801-2","article-title":"Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis","volume":"15","author":"Yoshikawa","year":"2025","journal-title":"Sci Rep"},{"key":"R20-20260609","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3389\/fphar.2018.01425","article-title":"FKBP ligands-where we are and where to go?","volume":"9","author":"Kolos","year":"2018","journal-title":"Front Pharmacol"},{"key":"R21-20260609","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1097\/00007890-199560120-00035","article-title":"Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK5061,2","volume":"60","author":"Shirakata","year":"1995","journal-title":"Transplantation"},{"key":"R22-20260609","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2125.2003.02008.x","article-title":"Factors affecting variability in distribution of tacrolimus in liver transplant recipients","volume":"57","author":"Zahir","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R23-20260609","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/bcp.15946","article-title":"Should we abandon therapeutic drug monitoring of tacrolimus in whole blood and move to intracellular concentration measurements?","volume":"91","author":"Udomkarnjananun","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"R24-20260609","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/fcp.12412","article-title":"Tacrolimus diffusion across the peripheral mononuclear blood cell membrane: impact of drug transporters","volume":"33","author":"Tron","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"R25-20260609","doi-asserted-by":"crossref","first-page":"e0230195","DOI":"10.1371\/journal.pone.0230195","article-title":"Pharmacogenetic-whole blood and intracellular pharmacokinetic-pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients","volume":"15","author":"Tron","year":"2020","journal-title":"PLOS One"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:25:42Z","timestamp":1781018742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001487","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"2026-01-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}